# BrainsWay Ltd. American (BWAY) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $14.15, market value $569 million.

## Valuation
- **P/E (trailing): 61.5×** (5-yr avg 94.3×, 3-yr avg 94.3×). BrainsWay Ltd. American trades at 61.5× trailing earnings, well below its own five-year average of 94.3×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 27.9×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 9.4×**. Each dollar of revenue is priced at 9.4×.
- **Price / book: 6.9×**. The shares trade at 6.9× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 37.4×**. Enterprise value is 37.4× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 1.0%** (5-yr avg 1.5%). Free cash flow equals 1.0% of the market value, below its five-year average of 1.5%, so the shares are pricier on cash than usual.
- **Earnings yield: 1.6%**. The inverse of the P/E: 1.6% of the price is earned each year.

## Profitability
- **Gross margin: 75.3%**. BrainsWay Ltd. American keeps 75.3% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 12.5%**. 12.5% of revenue is left after running the business.
- **Net margin: 14.6%**. 14.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 10.4%**. 10.4% on shareholders' equity is solid.
- **Return on invested capital: 68.1%**. Return on all capital, debt included, is 68.1%: comfortably above what that capital costs.
- **Return on assets: 8.4%**. Each dollar of assets produces 8.4% of profit.

## Growth
- **Revenue growth (1 yr): 27.3%** (3-yr 24.3%/yr, 5-yr 18.8%/yr). Revenue grew 27.3% over the last year, against 18.8% a year compounded over five years: growth is accelerating.

## Financial health
- **Debt to equity: 0.09**. Debt is 0.09 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. BrainsWay Ltd. American holds more cash than debt.
- **Interest coverage: 3.4×**. Operating profit covers interest 3.4× over, a safe margin.
- **Current ratio: 3.83** (quick 3.51). Current assets cover the next year's liabilities 3.83 times.
- **Altman Z-score: 10.76**. A Z-score of 10.76 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. BrainsWay Ltd. American does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 77.2%** (YTD 48.8%, 3-mo 1.9%). The shares are up 77.2% over twelve months including dividends.
- **From 52-week high: -18.7%** (98.3% above the low). Trading 19% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 42**. An RSI of 42 is neutral.
- **Beta (1 yr): 1.89** (volatility 54%). Beta of 1.89 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BWAY · Page: https://foliofundamentals.com/stocks/bway

Not investment advice.